FENC Revenue second quarter 2026 Y/Y Growth Comment
Fennec Pharmaceuticals Inc reported Revenue surge of 85.22% year on year in the second quarter 2026, to $ 17.87 millions, this is lower than Fennec Pharmaceuticals Inc 's recent average Revenue surge of 111.56%.
Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 15 other companies have achieved higher Revenue growth. While Fennec Pharmaceuticals Inc ' s Revenue jump of 85.22% ranks overall at the positon no. 310 in the second quarter 2026.
FENC Revenue ( Y/Y Growth %)
2026
2025
2024
2023
4th Quarter
December
-
73.99 %
-18.69 %
532.47 %
3rd Quarter
September
-
78.77 %
6.9 %
-
2nd Quarter
June
85.22 %
32.92 %
118.02 %
-
1st Quarter
March
72.69 %
-65.52 %
1410.71 %
-
FY
-
-6.08 %
123.46 %
-
Financial Statements
Fennec Pharmaceuticals Inc 's second quarter 2026 Revenue
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Fennec Pharmaceuticals Inc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
257.03 %
-0.55 %
-100 %
(Dec 31 2014)
FENC's II. Quarter Q/Q Revenue Comment
Fennec Pharmaceuticals Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 18.29%, to $ 17.87 millions, from $15.11 millions in the first quarter. FENC is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Biotechnology & Pharmaceuticals industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Fennec Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 544.
Fennec Pharmaceuticals Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 18.29%, to $ 17.87 millions, from $15.11 millions in the first quarter. FENC is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Biotechnology & Pharmaceuticals industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Fennec Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 544.
Fennec Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 30 2026)
12 Months Ending (Mar 31 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending
$ 59.22
$ 51.00
$ 44.64
$ 38.79
$ 33.30
Y / Y Revenue Growth (TTM)
77.83 %
64.98 %
-6.09 %
-21.39 %
-31.88 %
Year on Year Revenue Growth Overall
Ranking
# 269
# 3554
# 3494
# 3646
# 3689
Seqeuential Revenue Change (TTM)
16.12 %
14.24 %
15.09 %
16.48 %
7.73 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 269
# 3554
# 3494
# 3646
# 3689
Cumulative Revenue growth Comment
Fennec Pharmaceuticals Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 77.83% year on year, to $ 59 millions if the fiscal year would have ended in Jun 30 2026. Fennec Pharmaceuticals Inc 's trailing twelve months Revenue growth was higher than company's average 41.33% and higher than 64.98% growth in Mar 31 2026. But from twelve months ended Mar 31 2026 rise was beneth at 16.12 % from $51 millions achieved in the period from Mar 31 2026 to Jun 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at41.33%. The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 16.12 % increase from $51 millions in the period from Mar 31 2026 to Jun 30 2025.
In the Healthcare sector 476 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 269, from total ranking in previous quarter at 3554.
Fennec Pharmaceuticals Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 77.83% year on year, to $ 59 millions if the fiscal year would have ended in Jun 30 2026. Fennec Pharmaceuticals Inc 's trailing twelve months Revenue growth was higher than company's average 41.33% and higher than 64.98% growth in Mar 31 2026. But from twelve months ended Mar 31 2026 rise was beneth at 16.12 % from $51 millions achieved in the period from Mar 31 2026 to Jun 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at41.33%. The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 16.12 % increase from $51 millions in the period from Mar 31 2026 to Jun 30 2025.
In the Healthcare sector 476 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 269, from total ranking in previous quarter at 3554.
About Fennec Pharmaceuticals Inc Revenue Growth Rates (FENC), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
137.00%